What does “prevention” mean in contemporary AF management?
Atrial fibrillation (AF) prevention includes primary prevention (reducing incident AF through upstream risk factor modification) and secondary prevention (slowing AF progression, reducing recurrence and burden, and preventing AF-related adverse outcomes). Current US and European guidelines characterize AF as a staged, progressive disease, supporting early, longitudinal intervention.¹,²
Which prevention strategies are best supported by evidence?
Guideline-directed AF prevention prioritizes weight management, blood pressure control, treatment of sleep-disordered breathing, exercise optimization, alcohol reduction, and smoking cessation.¹,² These interventions improve rhythm-control durability and procedural outcomes.
Does early rhythm control serve a preventive role?
Yes. EAST-AFNET 4 demonstrated that early rhythm control—using antiarrhythmic drugs and/or catheter ablation—reduced cardiovascular death, stroke, and hospitalization in patients with early AF and concomitant cardiovascular conditions.³ CABANA showed that catheter ablation is associated with a lower AF recurrence rate than drug therapy.⁴
Is first-line ablation a prevention strategy?
In patients with paroxysmal AF, the STOP AF First trial showed cryoballoon ablation was superior to antiarrhythmic drug therapy for arrhythmia-free survival, supporting early intervention to limit disease progression.⁵
What innovations affect prevention today?
The ADVENT trial demonstrated pulsed field ablation was noninferior to conventional thermal ablation for efficacy and safety, accelerating adoption of earlier rhythm-control strategies.⁶
Key challenges include integrating structured risk-factor programs, selecting endpoints beyond recurrence alone, and ensuring equitable access to early AF intervention.¹,²
References
- Joglar JA, Chung MK, Armbruster AL, et al. 2023 ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation. J Am Coll Cardiol. 2024;83(1):109-279. doi:10.1016/j.jacc.2023.08.017
- Van Gelder IC, Kotecha D, Rienstra M, et al. 2024 ESC guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2024;45(36):3314-3414. doi:10.1093/eurheartj/ehae176
- Kirchhof P, Camm AJ, Goette A, et al. Early rhythm-control therapy in patients with atrial fibrillation. N Engl J Med. 2020;383(14):1305-1316. doi:10.1056/NEJMoa2019422
- Packer DL, Mark DB, Robb RA, et al. Effect of catheter ablation vs antiarrhythmic drug therapy on mortality and cardiovascular outcomes in atrial fibrillation (CABANA). JAMA. 2019;321(13):1261-1274. doi:10.1001/jama.2019.0693
- Wazni OM, Dandamudi G, Sood N, et al. Cryoballoon ablation as initial therapy for atrial fibrillation (STOP AF First). N Engl J Med. 2021;384(4):316-324. doi:10.1056/NEJMoa2029554
- Reddy VY, Anic A, Koruth J, et al. Pulsed field ablation vs thermal ablation for paroxysmal atrial fibrillation (ADVENT). N Engl J Med. 2023;389(4):316-327. doi:10.1056/NEJMoa2307291